Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an update.
Gunilla Osswald, CEO of BioArctic AB, has been named Uppsala University’s Alumnus of the Year 2025, acknowledging her visionary leadership and contributions to science and technology. This recognition highlights her role in developing lecanemab, a groundbreaking Alzheimer’s treatment, and underscores her influence as a role model, particularly for women in STEM fields, reinforcing BioArctic’s position as a leader in neurodegenerative disease research.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. The company is known for developing Leqembi® (lecanemab), the first drug proven to slow the progression of Alzheimer’s disease. BioArctic collaborates with Eisai for global commercialization and regulatory interactions and holds a broad research portfolio that includes treatments for Parkinson’s disease, ALS, and other Alzheimer’s projects, utilizing their proprietary BrainTransporter™ technology.
Average Trading Volume: 311,107
Technical Sentiment Signal: Buy
Current Market Cap: SEK25.69B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.